Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.
Completed · Phase 3
Conditions studied: Renal Failure
In brief
Open label, prospective, single-center, randomized, two sequence, three period crossover study to compare the steady state pharmacokinetics of LCP-Tacro tables to generic tacrolimus capsules administered twice daily in stable African-American renal transplant patients.
Key facts
- Study ID
- NCT01962922
- Run by
- Veloxis Pharmaceuticals
- People needed
- 50
- Starts
- 2013-11-01
- Expected to finish
- 2015-08-01
- Last updated by the study team
- 2018-06-06
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18-80 old, male or female
- African Americans
- Willing to give written informed consent and to comply with study visits and restrictions, including being able to speak, write and understand English
- Pt who have received a primary or secondary transplant
- Pt least 6 (six) mth post-transplant and on a stable dose of tacrolimus
- BMI ≥19
- Pt who are sero-positive for Hepatitis B or C positive may also be enrolled
- Pt maintained on concurrent immunosuppression with stable doses during screening
- Pt on a proton PPI remain on the same PPI formulation and dose during the PK portion of the study.
- During PK phase Only: Pt taking any medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food supplements (including grapefruit, and pomegranate products), or medications must continue the same dose and are willing to continue the same dose/routine
- During PK phase Only: the patient is not scheduled to begin any new medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food
You may not qualify if…
- Evidence of acute rejection episode within the past three months
- Pt not Africa-American
- Recipients of organ transplants other than kidney
- Known to be HIV positive at transplant
- Pt with recurrent focal segmental glomerulosclerosis (FSGS)
- Pt with any severe medical condition (including infection) requiring acute or chronic treatment
- Pt with a positive DSA
- Pt with a positive BK virus results
- GFR < 25 ml/min measured by MDRD4 as SOC within last 30 days
- Patients with AST, ALT, total bilirubin > 2.5 x ULN or evidence of severe liver disease
- Pt with WBC < to 2000/mm3 or ANC < to 1500 mm3 with PLT < 75,000/mm3 or HGB < 8 g/dl
- Pt with mental or physical conditions or known non-adherence
- Presence of intractable immunosuppressant complications of side effects resulting in dose adjustment of tacrolimus
- Exposed to investigational therapy within 30 days prior to enrollment
- No anticipated changes in the immunosuppressive regimen, other than those specified by the study protocol
- Pt with severe diabetic gastroparesis or other severe GI disturbances
- Pt who have underwent gastric banding or gastric bypass at any time pre or post-transplant
- Pregnant or nursing (lactating) women, or planning to become pregnant
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC of method
Where it is running
- University of Illinois, Chicago — Chicago, Illinois, United States
- Washingto University School of Medicine — St Louis, Missouri, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.